Current Opinion in Investigational Drugs
Archive
Current Opinion in Investigational Drugs, Volume 3
Paper alert T Jones, S Doggrell, Gasparo M de, M Williams, RE Hurst, G Damia Current Opinion in Investigational Drugs 2002, 3 :1-9 (31 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :10-12 (31 [PDF ]
Patent alert IN Duncan, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :13-32 (31 [PDF ]
Memory T-cells in non-lymphoid tissues. LS Cauley, RJ Hogan, DL Woodland Current Opinion in Investigational Drugs 2002, 3 :33-36 (31 [PDF ] [PubMed ] [Related articles ]
Update on human papillomavirus vaccines for cervical cancer. MA Steller Current Opinion in Investigational Drugs 2002, 3 :37-47 (31 [PDF ] [PubMed ] [Related articles ]
StaphVAX (Nabi). T Jones Current Opinion in Investigational Drugs 2002, 3 :48-50 (31 [PDF ] [PubMed ] [Related articles ]
Meningitis C vaccine (North American Vaccine). M Lattanzi, Giudice G Del Current Opinion in Investigational Drugs 2002, 3 :51-53 (31 [PDF ] [PubMed ] [Related articles ]
Varivax (Merck & Co). T Jones Current Opinion in Investigational Drugs 2002, 3 :54-57 (31 [PDF ] [PubMed ] [Related articles ]
Overview: Why are corticosteroids ineffective in COPD? IM Adcock, KF Chung Current Opinion in Investigational Drugs 2002, 3 :58-60 (31 [PDF ] [PubMed ] [Related articles ]
Antibiotics as anti-inflammatory agents. M T Labro Current Opinion in Investigational Drugs 2002, 3 :61-68 (31 [PDF ] [PubMed ] [Related articles ]
Adenosine receptor ligands as potential therapeutics in asthma. JR Fozard, C McCarthy Current Opinion in Investigational Drugs 2002, 3 :69-77 (31 [PDF ] [PubMed ] [Related articles ]
Ciclesonide (Byk Gulden). G Dent Current Opinion in Investigational Drugs 2002, 3 :78-83 (31 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Antiarrhythmics in atrial fibrillation. B Freestone, GYH Lip Current Opinion in Investigational Drugs 2002, 3 :84-88 (31 [PDF ] [PubMed ] [Related articles ]
Conivaptan (Yamanouchi). A Martinez-Castelao Current Opinion in Investigational Drugs 2002, 3 :89-95 (31 [PDF ] [PubMed ] [Related articles ]
CVT-510 (CV Therapeutics). A Zaza Current Opinion in Investigational Drugs 2002, 3 :96-100 (31 [PDF ] [PubMed ] [Related articles ]
Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. K Jardemark, M L Wadenberg, P Grillner, TH Svensson Current Opinion in Investigational Drugs 2002, 3 :101-105 (31 [PDF ] [PubMed ] [Related articles ]
5-HT2A antagonists in psychiatric disorders. Angelis L de Current Opinion in Investigational Drugs 2002, 3 :106-112 (31 [PDF ] [PubMed ] [Related articles ]
Aripiprazole (Otsuka Pharmaceutical Co). V Ozdemir, J Fourie, F Ozdener Current Opinion in Investigational Drugs 2002, 3 :113-120 (31 [PDF ] [PubMed ] [Related articles ]
Perospirone (Sumitomo Pharmaceuticals). Paulis T de Current Opinion in Investigational Drugs 2002, 3 :121-129 (31 [PDF ] [PubMed ] [Related articles ]
Overview: Immunotherapy for Cancer - Is it time for the kitchen sink? TA Davis Current Opinion in Investigational Drugs 2002, 3 :130-131 (31 [PDF ] [PubMed ] [Related articles ]
Epitope identification and vaccine design for cancer immunotherapy. A Sette, E Keogh, G Isjioka, J Sidney, S Tangri, B Livingston, D McKinney, M Newman, R Chesnut, J Fikes Current Opinion in Investigational Drugs 2002, 3 :132-139 (31 [PDF ] [PubMed ] [Related articles ]
Cancer vaccines, a critical review - Part I MS Mitchell Current Opinion in Investigational Drugs 2002, 3 :140-149 (31 [PDF ] [PubMed ] [Related articles ]
Cancer vaccines, a critical review - Part II MS Mitchell Current Opinion in Investigational Drugs 2002, 3 :150-158 (31 [PDF ] [PubMed ] [Related articles ]
GMK (Progenics Pharmaceuticals). KL Knutson Current Opinion in Investigational Drugs 2002, 3 :159-164 (31 [PDF ] [PubMed ] [Related articles ]
Bexxar (Corixa GlaxoSmithKline). B Cheson Current Opinion in Investigational Drugs 2002, 3 :165-170 (31 [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, L Hofseth, S Doggrell, D Lane, M Williams, RE Hurst, G Damia Current Opinion in Investigational Drugs 2002, 3 :171-182 (26 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :183-186 (26 [PDF ]
Patent alert OA Phillips, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :187-205 (26 [PDF ]
Novel cephalosporins for the treatment of MRSA infections. TW Glinka Current Opinion in Investigational Drugs 2002, 3 :206-217 (26 [PDF ] [PubMed ] [Related articles ]
The impact of carbapenemases on antimicrobial development and therapy. DM Livermore Current Opinion in Investigational Drugs 2002, 3 :218-224 (26 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Iseganan (IntraBiotics Pharmaceuticals). JH Toney Current Opinion in Investigational Drugs 2002, 3 :225-228 (26 [PDF ] [PubMed ] [Related articles ]
Dalbavancin (Biosearch Italia/Versicor). M Steiert, F-J Schmitz Current Opinion in Investigational Drugs 2002, 3 :229-233 (26 [PDF ] [PubMed ] [Related articles ]
Abetimus (La Jolla Pharmaceuticals). H-M Lorenz Current Opinion in Investigational Drugs 2002, 3 :234-239 (26 [PDF ] [PubMed ] [Related articles ]
Valdecoxib (Pharmacia). AW Gotta Current Opinion in Investigational Drugs 2002, 3 :240-245 (26 [PDF ] [PubMed ] [Related articles ]
Ximelagatran (AstraZeneca). R Hopfner Current Opinion in Investigational Drugs 2002, 3 :246-251 (26 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
DPC-423 (Bristol-Myers Squibb). M Taglialatela Current Opinion in Investigational Drugs 2002, 3 :252-254 (26 [PDF ] [PubMed ] [Related articles ]
Overview: The green evolution of psychotropic drugs. M Briley, C Moret Current Opinion in Investigational Drugs 2002, 3 :255-256 (26 [PDF ] [PubMed ] [Related articles ]
Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. NMJ Rupniak Current Opinion in Investigational Drugs 2002, 3 :257-261 (26 [PDF ] [PubMed ] [Related articles ]
Nicotine dependence: The role for antidepressants and anxiolytics. MA Sullivan, LS Covey Current Opinion in Investigational Drugs 2002, 3 :262-271 (26 [PDF ] [PubMed ] [Related articles ]
Tomoxetine (Eli Lilly & Co). A Preti Current Opinion in Investigational Drugs 2002, 3 :272-276 (26 [PDF ] [PubMed ] [Related articles ]
gamma-Hydroxybutyrate (Orphan Medical). G Tunnicliff, BU Raess Current Opinion in Investigational Drugs 2002, 3 :278-283 (26 [PDF ] [PubMed ] [Related articles ]
CEE-03-310 (CeNeS Pharmaceuticals). DN Eder Current Opinion in Investigational Drugs 2002, 3 :284-288 (26 [PDF ] [PubMed ] [Related articles ]
Deramciclane (Egis). S Koks, E Vasar Current Opinion in Investigational Drugs 2002, 3 :289-294 (26 [PDF ] [PubMed ] [Related articles ]
Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. S Huang, PJ Houghton Current Opinion in Investigational Drugs 2002, 3 :295-304 (26 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Fulvestrant (AstraZeneca). SRD Johnston Current Opinion in Investigational Drugs 2002, 3 :305-312 (26 [PDF ] [PubMed ] [Related articles ]
Tipifarnib (Janssen Pharmaceutica). P Norman Current Opinion in Investigational Drugs 2002, 3 :313-319 (26 [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, T Jones, A Palmer, S Doggrell, F Barone, Gasparo M de, RE Hurst, G Damia Current Opinion in Investigational Drugs 2002, 3 :321-335 (18 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :336-339 (18 [PDF ]
Patent alert OA Phillips, I Duncan, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :340-364 (18 [PDF ]
Development of WF10, a novel macrophage-regulating agent. MS McGrath, JO Kahn, BG Herndier Current Opinion in Investigational Drugs 2002, 3 :365-373 (18 [PDF ] [PubMed ] [Related articles ]
Heterologous "prime-boost" vaccination strategies for HIV-1: Augmenting cellular immune responses. MJ Newman Current Opinion in Investigational Drugs 2002, 3 :374-378 (18 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Sch-351125 and Sch-350634 (Schering Plough). JA Este Current Opinion in Investigational Drugs 2002, 3 :379-383 (18 [PDF ] [PubMed ] [Related articles ]
Fosamprenavir Vertex Pharmaceuticals/GlaxoSmithKline. AH Corbett, ADM Kashuba Current Opinion in Investigational Drugs 2002, 3 :384-390 (18 [PDF ] [PubMed ] [Related articles ]
Remune Immune Response Corp. D Lai, T Jones Current Opinion in Investigational Drugs 2002, 3 :391-399 (18 [PDF ] [PubMed ] [Related articles ]
Chemokines in transplant rejection. CA Haskell, S Ribeiro, R Horuk Current Opinion in Investigational Drugs 2002, 3 :399-405 (18 [PDF ] [PubMed ] [Related articles ]
Targeting IL-15 as a therapeutic strategy in organ transplant rejection. XG Smith, EM Bolton, JA Bradley Current Opinion in Investigational Drugs 2002, 3 :406-410 (18 [PDF ] [PubMed ] [Related articles ]
Nuvion (Protein Design Labs). V Trajkovic Current Opinion in Investigational Drugs 2002, 3 :411-414 (18 [PDF ] [PubMed ] [Related articles ]
ABCA1: Regulation, function and relationship to atherosclerosis. OL Francone, RJ Aiello Current Opinion in Investigational Drugs 2002, 3 :415-419 (18 [PDF ] [PubMed ] [Related articles ]
Use of recombinant apolipoproteins in vascular diseases: The case of apoA-I. G Chiesa, CR Sirtori Current Opinion in Investigational Drugs 2002, 3 :420-426 (18 [PDF ] [PubMed ] [Related articles ]
Ezetimibe (Schering-Plough). CQ Meng Current Opinion in Investigational Drugs 2002, 3 :427-432 (18 [PDF ] [PubMed ] [Related articles ]
AGI-1067 (AtheroGenics). GM Hatch Current Opinion in Investigational Drugs 2002, 3 :433-436 (18 [PDF ] [PubMed ] [Related articles ]
Overview: Cannabis: Old medicine with new promise for neurological disorders. GT Carter, P Weydt Current Opinion in Investigational Drugs 2002, 3 :437-440 (18 [PDF ] [PubMed ] [Related articles ]
Current treatment options in neuropathic pain. K Hempenstall, ASC Rice Current Opinion in Investigational Drugs 2002, 3 :441-448 (18 [PDF ] [PubMed ] [Related articles ]
Sensitization: Its role in primary headache. L Bendtsen Current Opinion in Investigational Drugs 2002, 3 :449-453 (18 [PDF ] [PubMed ] [Related articles ]
Antidepressants in pain management. GT Carter, MD Sullivan Current Opinion in Investigational Drugs 2002, 3 :454-458 (18 [PDF ] [PubMed ] [Related articles ]
EN-3231 (Endo Pharmaceuticals). N Monck Current Opinion in Investigational Drugs 2002, 3 :459-462 (18 [PDF ] [PubMed ] [Related articles ]
E-TRANS fentanyl (ALZA Corp). K Mystakidou Current Opinion in Investigational Drugs 2002, 3 :463-469 (18 [PDF ] [PubMed ] [Related articles ]
Gabapentin (Pfizer). G Wheeler Current Opinion in Investigational Drugs 2002, 3 :470-477 (18 [PDF ] [PubMed ] [Related articles ]
Overview: The art of cancer drug screening: molecular target versus milieu-based screens. CL Sawyers, EA Sausville Current Opinion in Investigational Drugs 2002, 3 :478-481 (18 [PDF ] [PubMed ] [Related articles ]
Small molecules in anti-angiogenic therapy . R Giavazzi, MI Nicoletti Current Opinion in Investigational Drugs 2002, 3 :482-491 (18 [PDF ] [PubMed ] [Related articles ]
Imatinib (Novartis). IR Radford Current Opinion in Investigational Drugs 2002, 3 :492-499 (18 [PDF ] [PubMed ] [Related articles ]
BMS-275291 (Bristol-Myers Squibb). V Poulaki Current Opinion in Investigational Drugs 2002, 3 :500-504 (18 [PDF ] [PubMed ] [Related articles ]
Paper alert F Barone, D Lane, A Palmer, RE Hurst Current Opinion in Investigational Drugs 2002, 3 :505-513 (30 [PDF ]
Patent selection H AM Mucke Current Opinion in Investigational Drugs 2002, 3 :514-516 (30 [PDF ]
Patent alert N Press, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :517-532 (30 [PDF ]
Antibiotics for the treatment of onchocerciasis and other filarial infections. A Hoerauf, O Adjei, DW Buttner Current Opinion in Investigational Drugs 2002, 3 :533-537 (30 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Topical treatment for cutaneous leishmaniasis. T Garnier, SL Croft Current Opinion in Investigational Drugs 2002, 3 :538-544 (30 [PDF ] [PubMed ] [Related articles ]
Artemotil (Artecef). RA Yeates Current Opinion in Investigational Drugs 2002, 3 :545-549 (30 [PDF ] [PubMed ] [Related articles ]
Miltefosine (Zentaris). R Kaminsky Current Opinion in Investigational Drugs 2002, 3 :550-554 (30 [PDF ] [PubMed ] [Related articles ]
Ravuconazole (Eisai/Bristol-Myers Squibb). S Arikan, JH Rex Current Opinion in Investigational Drugs 2002, 3 :555-561 (30 [PDF ] [PubMed ] [Related articles ]
Overview: Interleukin-16 and its role in inflammatory bowel disease. D Seegert, S Schreiber Current Opinion in Investigational Drugs 2002, 3 :562-564 (30 [PDF ] [PubMed ] [Related articles ]
Role of neurotrophins in inflammation of the gut. M Reinshagen, Boyen G von, G Adler, M Steinkamp Current Opinion in Investigational Drugs 2002, 3 :565-568 (30 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Angiotensin II as a pro-inflammatory mediator. MI Phillips, S Kagiyama Current Opinion in Investigational Drugs 2002, 3 :569-577 (30 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Sampatrilat (Shire). K Allikmets Current Opinion in Investigational Drugs 2002, 3 :578-581 (30 [PDF ] [PubMed ] [Related articles ]
Treprostinil sodium (Pharmacia). SC Chattaraj Current Opinion in Investigational Drugs 2002, 3 :582-586 (30 [PDF ] [PubMed ] [Related articles ]
Cholecystokinin and eating. C Beglinger Current Opinion in Investigational Drugs 2002, 3 :587-588 (30 [PDF ] [PubMed ] [Related articles ]
Tachykinin receptor antagonists in irritable bowel syndrome. A Lecci, C Valenti, CA Maggi Current Opinion in Investigational Drugs 2002, 3 :589-601 (30 [PDF ] [PubMed ] [Related articles ]
Topiglan (MacroChem). CG McMahon Current Opinion in Investigational Drugs 2002, 3 :602-606 (30 [PDF ] [PubMed ] [Related articles ]
Vardenafil (Bayer Yakuhin). F Sommer, U Engelmann Current Opinion in Investigational Drugs 2002, 3 :607-614 (30 [PDF ] [PubMed ] [Related articles ]
Methylnaltrexone (Progenics). Ponti F De Current Opinion in Investigational Drugs 2002, 3 :614-620 (30 [PDF ] [PubMed ] [Related articles ]
Dexloxiglumide (Rotta Research Lab). G Varga Current Opinion in Investigational Drugs 2002, 3 :621-626 (30 [PDF ] [PubMed ] [Related articles ]
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. A Aparicio, JS Weber Current Opinion in Investigational Drugs 2002, 3 :627-633 (30 [PDF ] [PubMed ] [Related articles ]
Chemosensitization of solid tumors by modulation of resistance mechanisms. IA Cree, L Knight, Nicolantonio F Di, S Sharma, T Gulliford Current Opinion in Investigational Drugs 2002, 3 :634-640 (30 [PDF ] [PubMed ] [Related articles ]
Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis. IA Cree, L Knight, Nicolantonio F Di, S Sharma, T Gulliford Current Opinion in Investigational Drugs 2002, 3 :641-647 (30 [PDF ] [PubMed ] [Related articles ]
MitoExtra (SuperGen). K Grosios Current Opinion in Investigational Drugs 2002, 3 :648 (30 [PDF ] [PubMed ] [Related articles ]
Paper alert T Jones, F Barone, M Williams, A Palmer, G Damia, RE Hurst, Gasparo M de Current Opinion in Investigational Drugs 2002, 3 :653-661 (16 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :662-663 (16 [PDF ]
Patent alert N Press, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :664-679 (16 [PDF ]
Prospects for hepatitis C virus therapeutics: Levovirin and viramidine as improved derivatives of ribavirin. J Watson Current Opinion in Investigational Drugs 2002, 3 :680-683 (16 [PDF ] [PubMed ] [Related articles ]
XTL-001 (XTL Pharmaceuticals). G Witherell Current Opinion in Investigational Drugs 2002, 3 :684-692 (16 [PDF ] [PubMed ] [Related articles ]
Interferon-a (Amarillo Biosciences). DL Barnard Current Opinion in Investigational Drugs 2002, 3 :693-697 (16 [PDF ] [PubMed ] [Related articles ]
Thymosin a1 (SciClone Pharmaceuticals). A Billich Current Opinion in Investigational Drugs 2002, 3 :698-707 (16 [PDF ] [PubMed ] [Related articles ]
Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. EC Bornhovd, WHC Burgdorf, A Wollenberg Current Opinion in Investigational Drugs 2002, 3 :708-712 (16 [PDF ] [PubMed ] [Related articles ]
Intravenous immunoglobulin: An emerging treatment for immune-mediated skin diseases. A Rutter, TA Luger Current Opinion in Investigational Drugs 2002, 3 :713-719 (16 [PDF ] [PubMed ] [Related articles ]
Pimecrolimus (Novartis). RE Schopf Current Opinion in Investigational Drugs 2002, 3 :720-724 (16 [PDF ] [PubMed ] [Related articles ]
IDEC-131 (IDEC/Eisai). FJ Dumont Current Opinion in Investigational Drugs 2002, 3 :725-734 (16 [PDF ] [PubMed ] [Related articles ]
Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and prevention. N Giannoukakis, M Pietropaolo, M Trucco Current Opinion in Investigational Drugs 2002, 3 :735-751 (16 [PDF ] [PubMed ] [Related articles ]
Pegvisomant (Pharmacia). V Goffin, P Touraine Current Opinion in Investigational Drugs 2002, 3 :752-757 (16 [PDF ] [PubMed ] [Related articles ]
Exubera (Inhale Therapeutic Systems). S Bindra, WT Cefalu Current Opinion in Investigational Drugs 2002, 3 :758-762 (16 [PDF ] [PubMed ] [Related articles ]
Overview: Herbal medicines for neurological diseases. S Kienzle-Horn Current Opinion in Investigational Drugs 2002, 3 :763-767 (16 [PDF ] [PubMed ] [Related articles ]
Estrogen and Alzheimer's disease. A LeBlanc Current Opinion in Investigational Drugs 2002, 3 :768-773 (16 [PDF ] [PubMed ] [Related articles ]
Neural stem cells and neurodegeneration. A Storch, J Schwarz Current Opinion in Investigational Drugs 2002, 3 :774-781 (16 [PDF ] [PubMed ] [Related articles ]
Proteopathy: The next therapeutic frontier? LC Walker, Harry LeVine III Current Opinion in Investigational Drugs 2002, 3 :782-787 (16 [PDF ] [PubMed ] [Related articles ]
Nefiracetam (Daiichi Seiyaku). F Crespi Current Opinion in Investigational Drugs 2002, 3 :788-793 (16 [PDF ] [PubMed ] [Related articles ]
Rasagiline (Teva Pharmaceutical). A Kupsch Current Opinion in Investigational Drugs 2002, 3 :794-797 (16 [PDF ] [PubMed ] [Related articles ]
Memantine (Merz). GJ Kilpatrick, GS Tilbrook Current Opinion in Investigational Drugs 2002, 3 :798-806 (16 [PDF ] [PubMed ] [Related articles ]
Overview: Interactions between ionizing radiation and drugs in head and neck cancer: How can we maximize the therapeutic index? KJ Harrington, CM Nutting Current Opinion in Investigational Drugs 2002, 3 :807-811 (16 [PDF ] [PubMed ] [Related articles ]
Reversers of the multidrug resistance transporter P-glycoprotein. WD Stein Current Opinion in Investigational Drugs 2002, 3 :812-817 (16 [PDF ] [PubMed ] [Related articles ]
Biricodar (Vertex Pharmaceuticals). S Dey Current Opinion in Investigational Drugs 2002, 3 :818 (16 [PDF ] [PubMed ] [Related articles ]
Erratum. Current Opinion in Investigational Drugs 2002, 3 :824 (29 [PDF ]
Paper alert S Hunt, D Lane, M Williams, G Damia, RE Hurst Current Opinion in Investigational Drugs 2002, 3 :825-829 (24 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :830-832 (24 [PDF ]
Patent alert I Duncan, N Press, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :833-847 (24 [PDF ]
AZD-2563 (AstraZeneca). AP Johnson Current Opinion in Investigational Drugs 2002, 3 :848-852 (24 [PDF ] [PubMed ] [Related articles ]
ATP-binding cassette transporters in macropages: Promising drug targets for treatment of cardiovascular disease. G Schmitz, W Drobnik Current Opinion in Investigational Drugs 2002, 3 :853-858 (24 [PDF ] [PubMed ] [Related articles ]
Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. PF Smith Current Opinion in Investigational Drugs 2002, 3 :859-864 (24 [PDF ] [PubMed ] [Related articles ]
BX-471 (Berlex). MJ Elices Current Opinion in Investigational Drugs 2002, 3 :865-869 (24 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Pexelizumab (Alexion). PA Whiss Current Opinion in Investigational Drugs 2002, 3 :870-877 (24 [PDF ] [PubMed ] [Related articles ]
Antithrombotics and thrombolytics in stroke. SA Mousa, O Iqbal, J Fareed Current Opinion in Investigational Drugs 2002, 3 :878-885 (24 [PDF ] [PubMed ] [Related articles ]
Superoxide, superoxide dismutase and ischemic injury. D Salvemini, S Cuzzocrea Current Opinion in Investigational Drugs 2002, 3 :886-895 (24 [PDF ] [PubMed ] [Related articles ]
Endothelium-targeted pharmacotherapeutics for the treatment of stroke. G Danton, BD Watson, R Prado, WD Dietrich Current Opinion in Investigational Drugs 2002, 3 :896-904 (24 [PDF ] [PubMed ] [Related articles ]
BIBR-1048 (Boehringer Ingelheim). D Mungall Current Opinion in Investigational Drugs 2002, 3 :905-907 (24 [PDF ] [PubMed ] [Related articles ]
Irampanel (Boehringer Ingelheim). V Feigin Current Opinion in Investigational Drugs 2002, 3 :908-910 (24 [PDF ] [PubMed ] [Related articles ]
Overview: Multiple sclerosis and gender. C Darlington Current Opinion in Investigational Drugs 2002, 3 :911-914 (24 [PDF ] [PubMed ] [Related articles ]
Conus peptides and neuroprotection. CE Heading Current Opinion in Investigational Drugs 2002, 3 :915-920 (24 [PDF ] [PubMed ] [Related articles ]
DP-VPA (D-Pharm). DM Labiner Current Opinion in Investigational Drugs 2002, 3 :921-923 (24 [PDF ] [PubMed ] [Related articles ]
Repinotan (Bayer). HL Lutsep Current Opinion in Investigational Drugs 2002, 3 :924-927 (24 [PDF ] [PubMed ] [Related articles ]
Overview: Nucleic acid therapeutics: A work in progress. JB Opalinska, AM Gewirtz Current Opinion in Investigational Drugs 2002, 3 :928-933 (24 [PDF ] [PubMed ] [Related articles ]
Antisense DNAs as targeted therapeutics for cancer: No longer a dream. YS Cho-Chung Current Opinion in Investigational Drugs 2002, 3 :934 (24 [PDF ] [PubMed ] [Related articles ]
Paper alert F Barone, M Daneshtalab, C Darlington, RE Hurst, M Williams Current Opinion in Investigational Drugs 2002, 3 :941-949 (15 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :950-953 (15 [PDF ]
Patent alert I Duncan, HAM Mucke, P Norman, N Press Current Opinion in Investigational Drugs 2002, 3 :954-974 (15 [PDF ]
Meningococcal vaccines CL Collins, AJ Pollard Current Opinion in Investigational Drugs 2002, 3 :975-979 (15 [PDF ] [PubMed ] [Related articles ]
Vaccines for Chlamydia trachomatis infections LM de la Maza, EM Peterson Current Opinion in Investigational Drugs 2002, 3 :980-986 (15 [PDF ] [PubMed ] [Related articles ]
Hepagene (PowderJect) T Jones Current Opinion in Investigational Drugs 2002, 3 :987-991 (15 [PDF ] [PubMed ] [Related articles ]
Arilvax (PowderJect) ADT Barrett Current Opinion in Investigational Drugs 2002, 3 :992-995 (15 [PDF ] [PubMed ] [Related articles ]
Varilrix (GlaxoSmithKline) AM Arvin Current Opinion in Investigational Drugs 2002, 3 :996-999 (15 [PDF ] [PubMed ] [Related articles ]
Regenerative medicine through mesenchymal stem cells for bone and cartilage repair D Noel, F Djouad, C Jorgensen Current Opinion in Investigational Drugs 2002, 3 :1000-1004 (15 [PDF ] [PubMed ] [Related articles ]
BAFF: A novel therapeutic target for autoimmunity SL Kalled Current Opinion in Investigational Drugs 2002, 3 :1005-1010 (15 [PDF ] [PubMed ] [Related articles ]
Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines Roon JAG van, JWJ Bijlsma, FPJG Lafeber Current Opinion in Investigational Drugs 2002, 3 :1011-1016 (15 [PDF ] [PubMed ] [Related articles ]
Eculizumab (Alexion) M Kaplan Current Opinion in Investigational Drugs 2002, 3 :1017-1023 (15 [PDF ] [PubMed ] [Related articles ]
Aldosterone antagonists in congestive heart failure J Soberman, CC Chafin, KT Weber Current Opinion in Investigational Drugs 2002, 3 :1024-1028 (15 [PDF ] [PubMed ] [Related articles ]
Current and new drugs for the treatment of arrhythmias J Auer, R Berent, T Weber, E Lassnig, B Eber Current Opinion in Investigational Drugs 2002, 3 :1029-1036 (15 [PDF ] [PubMed ] [Related articles ]
Amiodarone in the prevention and treatment of arrhythmia J Auer, R Berent, B Eber Current Opinion in Investigational Drugs 2002, 3 :1037-1044 (15 [PDF ] [PubMed ] [Related articles ]
Sudden cardiac death: From molecular biology and cellular electrophysiology to therapy I Kocic Current Opinion in Investigational Drugs 2002, 3 :1045-1050 (15 [PDF ] [PubMed ] [Related articles ]
S-0139 (Shionogi) Wong JR Wu Current Opinion in Investigational Drugs 2002, 3 :1051-1056 (15 [PDF ] [PubMed ] [Related articles ]
BMS-193884 and BMS-207940 (Bristol-Myers Squibb) M Hulpke-Wette, R Buchhorn Current Opinion in Investigational Drugs 2002, 3 :1057-1061 (15 [PDF ] [PubMed ] [Related articles ]
Positive modulators of AMPA receptors as a potential treatment for schizophrenia. W Danysz Current Opinion in Investigational Drugs 2002, 3 :1062-1066 (7 [PDF ] [PubMed ] [Related articles ]
Glycine modulators in schizophrenia DC Javitt Current Opinion in Investigational Drugs 2002, 3 :1067-1072 (15 [PDF ] [PubMed ] [Related articles ]
New antipsychotic agents for schizophrenia: Pharmacokinetics and metabolism update S Caccia Current Opinion in Investigational Drugs 2002, 3 :1073-1080 (15 [PDF ] [PubMed ] [Related articles ]
Positive modulators of AMPA receptors as a potential treatment for schizophrenia W Danysz Current Opinion in Investigational Drugs 2002, 3 :1081-1088 (15 [PDF ] [PubMed ] [Related articles ]
Overview: Immunotoxins in cancer therapy I Prastan, R Kreitman Current Opinion in Investigational Drugs 2002, 3 :1089-1091 (15 [PDF ] [PubMed ] [Related articles ]
Cetuximab (ImClone/Merck/Bristol-Myers Squibb) MS Kies, PM Harari Current Opinion in Investigational Drugs 2002, 3 :1092-1100 (15 [PDF ] [PubMed ] [Related articles ]
Paper alert E Boven, M Daneshtalab, G Damia, S Doggrell, T Jones, RE Hurst, A Palmer, M Williams Current Opinion in Investigational Drugs 2002, 3 :1101-1114 (9 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1115-1117 (9 [PDF ]
Patent alert I Duncan, HAM Mucke, P Norman, N Press Current Opinion in Investigational Drugs 2002, 3 :1118-1132 (9 [PDF ]
Eliminating HIV-1 reservoirs RJ Pomerantz Current Opinion in Investigational Drugs 2002, 3 :1133-1137 (9 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Immune reconstitution in HIV-1-infected patients N Imami, G Hardy, A Pires, C Burton, Lopez J Pido, C Mela, F Gotch Current Opinion in Investigational Drugs 2002, 3 :1138-1145 (9 [PDF ] [PubMed ] [Related articles ]
SJ-3366 Sam Jin Pharmaceutical M Baba Current Opinion in Investigational Drugs 2002, 3 :1146-1148 (9 [PDF ] [PubMed ] [Related articles ]
Recent advances in corticosteroids for the treatment of asthma G Bhalay, DA Sandham Current Opinion in Investigational Drugs 2002, 3 :1149-1156 (9 [PDF ] [PubMed ] [Related articles ]
Anti-IgE therapy of asthma KF Chung Current Opinion in Investigational Drugs 2002, 3 :1157-1160 (9 [PDF ] [PubMed ] [Related articles ]
ONO-6818 Cortech/Ono A Trfilieff Current Opinion in Investigational Drugs 2002, 3 :1161-1164 (9 [PDF ] [PubMed ] [Related articles ]
Roflumilast Altana Pharma P Reid Current Opinion in Investigational Drugs 2002, 3 :1165-1170 (9 [PDF ] [PubMed ] [Related articles ]
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia WP Jeske, JM Walenga Current Opinion in Investigational Drugs 2002, 3 :1171-1180 (9 [PDF ] [PubMed ] [Related articles ]
Heparin and low molecular weight heparin in thrombosis and beyond SA Mousa Current Opinion in Investigational Drugs 2002, 3 :1181-1186 (9 [PDF ] [PubMed ] [Related articles ]
Oxygen carriers TMS Chang Current Opinion in Investigational Drugs 2002, 3 :1187-1190 (9 [PDF ] [PubMed ] [Related articles ]
Vitronectin receptors in vascular disorders SA Mousa Current Opinion in Investigational Drugs 2002, 3 :1191-1195 (9 [PDF ] [PubMed ] [Related articles ]
ART-123 Asahi Kasei S Khorchidi, R Bantleon, R Kehbach, G Tepe, J Wiskirchen, SH Duda Current Opinion in Investigational Drugs 2002, 3 :1196-1198 (9 [PDF ] [PubMed ] [Related articles ]
Orexins (hypocretins): Their role in appetite and arousal A Preti Current Opinion in Investigational Drugs 2002, 3 :1199-1206 (9 [PDF ] [PubMed ] [Related articles ]
Drugs under investigation for attention-deficit hyperactivity disorder JB Schweitzer, HH Holcomb Current Opinion in Investigational Drugs 2002, 3 :1207-1211 (9 [PDF ] [PubMed ] [Related articles ]
Risperidone: A potential treatment for autism DJ Posey, CJ McDougle Current Opinion in Investigational Drugs 2002, 3 :1212-1216 (9 [PDF ] [PubMed ] [Related articles ]
Duloxetine Eli Lilly S Anttila, E Leinonen Current Opinion in Investigational Drugs 2002, 3 :1217-1221 (9 [PDF ] [PubMed ] [Related articles ]
MethyPatch Noven N Sane, JJ McGough Current Opinion in Investigational Drugs 2002, 3 :1222-1224 (9 [PDF ] [PubMed ] [Related articles ]
Escitalopram H Lundbeck AL McRae Current Opinion in Investigational Drugs 2002, 3 :1225-1229 (9 [PDF ] [PubMed ] [Related articles ]
Selegiline transdermal system Somerset I Mahmood Current Opinion in Investigational Drugs 2002, 3 :1230-1233 (9 [PDF ] [PubMed ] [Related articles ]
Endothelin receptor antagonists as therapeutic agents for cancer Wong JR Wu Current Opinion in Investigational Drugs 2002, 3 :1234-1239 (9 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Atrasentan Abbott P Norman Current Opinion in Investigational Drugs 2002, 3 :1240-1248 (9 [PDF ] [PubMed ] [Related articles ]
CCI-779 Wyeth L Elit Current Opinion in Investigational Drugs 2002, 3 :1249-1253 (9 [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, G Damia, S Doggrell, RE Hirst Current Opinion in Investigational Drugs 2002, 3 :1255-1263 (11 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1264-1266 (11 [PDF ]
Patent alert I Duncan, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :1267-1283 (11 [PDF ]
The impact of beta-lactamases on the development of novel antimicrobial agents K Bush Current Opinion in Investigational Drugs 2002, 3 :1284-1290 (11 [PDF ] [PubMed ] [Related articles ]
GM-CSF treatment for Crohn's disease: A stimulating new therapy? JN Wilk, JL Viney Current Opinion in Investigational Drugs 2002, 3 :1291-1296 (11 [PDF ] [PubMed ] [Related articles ]
Role of tumor necrosis factor in Crohn's disease S Ganesan, SPL Travis, T Ahmad, R Jazrawi Current Opinion in Investigational Drugs 2002, 3 :1297-1300 (11 [PDF ] [PubMed ] [Related articles ]
Therapeutic inhibitors of tumor necrosis factor in Crohn's disease S Ganesan, SPL Travis, T Ahmad, R Jazrawi Current Opinion in Investigational Drugs 2002, 3 :1301-1306 (11 [PDF ] [PubMed ] [Related articles ]
Tacrolimus (Fujisawa) AT Gewirtz, SV Sitaraman Current Opinion in Investigational Drugs 2002, 3 :1307-1311 (11 [PDF ] [PubMed ] [Related articles ]
Pleiotropic effects of HMG-CoA reductase inhibitors TMA Bocan Current Opinion in Investigational Drugs 2002, 3 :1312-1317 (11 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Combination therapy with statins H Gylling, TA Miettinen Current Opinion in Investigational Drugs 2002, 3 :1318-1323 (11 [PDF ] [PubMed ] [Related articles ]
S-18886 (Servier) SK Kakkos, AN Nicolaides Current Opinion in Investigational Drugs 2002, 3 :1324-1327 (11 [PDF ] [PubMed ] [Related articles ]
Avasimibe (Pfizer) JR Burnett, MW Huff Current Opinion in Investigational Drugs 2002, 3 :1328-1333 (11 [PDF ] [PubMed ] [Related articles ]
Pitavastatin (Nissan/Kowa Yakuhin/Novartis/Sankyo) N Flores Current Opinion in Investigational Drugs 2002, 3 :1334-1341 (11 [PDF ] [PubMed ] [Related articles ]
Utilizing brain imaging for analgesic drug development D Borsook, A Ploghaus, L Becerra Current Opinion in Investigational Drugs 2002, 3 :1342-1347 (11 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
COX-2 inhibition and the control of pain W Kiefer, G Dannhardt Current Opinion in Investigational Drugs 2002, 3 :1348-1358 (11 [PDF ] [PubMed ] [Related articles ]
Eletriptan (Pfizer) PJLM Strijbos, AA Parsons, A Fugell Current Opinion in Investigational Drugs 2002, 3 :1359-1368 (11 [PDF ] [PubMed ] [Related articles ]
Avinza (Elan) MR Semenchuk Current Opinion in Investigational Drugs 2002, 3 :1369-1372 (11 [PDF ] [PubMed ] [Related articles ]
Frovatriptan (Vernalis) HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1373-1380 (11 [PDF ] [PubMed ] [Related articles ]
Overview - Selective induction of tumor ischemia: Development of vascular targeting agents for cancer therapy DJ Chaplin, SA Hill Current Opinion in Investigational Drugs 2002, 3 :1381-1384 (11 [PDF ] [PubMed ] [Related articles ]
Erlotinib (OSI/Roche/Genentech) TE Kim, JR Murren Current Opinion in Investigational Drugs 2002, 3 :1385-1395 (11 [PDF ] [PubMed ] [Related articles ]
FR-901228 (Fujisawa/National Cancer Institute) DM Vigushin Current Opinion in Investigational Drugs 2002, 3 :1396-1402 (11 [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, RE Hurst, T Jones, M Williams Current Opinion in Investigational Drugs 2002, 3 :1403-1412 (11 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1413-1415 (11 [PDF ]
Patent alert I Duncan, HAM Mucke, P Norman, N Press Current Opinion in Investigational Drugs 2002, 3 :1416-1431 (11 [PDF ]
The role of caspofungin and the echinocandins in the antifungal armamentarium VA Morrison Current Opinion in Investigational Drugs 2002, 3 :1432-1436 (11 [PDF ] [PubMed ] [Related articles ]
DNA binding compounds targeting fungal pathogens: An emerging concept in the discovery of novel antifungal agents L Lou, M Velligan, C Roberts, DA Stevens, KV Clemons Current Opinion in Investigational Drugs 2002, 3 :1437-1445 (11 [PDF ] [PubMed ] [Related articles ]
Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). C Yeates Current Opinion in Investigational Drugs 2002, 3 :1446-1452 (11 [PDF ] [PubMed ] [Related articles ]
Overview: Transplantation tolerance - challenges and opportunities for drug development FJ Dumont Current Opinion in Investigational Drugs 2002, 3 :1453-1457 (11 [PDF ] [PubMed ] [Related articles ]
1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation L Adorini Current Opinion in Investigational Drugs 2002, 3 :1458-1463 (11 [PDF ] [PubMed ] [Related articles ]
Inolimomab (OPi). M Winkler Current Opinion in Investigational Drugs 2002, 3 :1464-1467 (11 [PDF ] [PubMed ] [Related articles ]
The role of aldosterone receptor blockade in the management of cardiovascular disease D Liew, H Krum Current Opinion in Investigational Drugs 2002, 3 :1468-1473 (11 [PDF ] [PubMed ] [Related articles ]
Clevidipine (The Medicines Company). H Zhang Current Opinion in Investigational Drugs 2002, 3 :1474-1482 (11 [PDF ] [PubMed ] [Related articles ]
Aliskiren (Speedel). K Allikmets Current Opinion in Investigational Drugs 2002, 3 :1479-1482 (11 [PDF ] [PubMed ] [Related articles ]
Ambrisentan (Myogen) GE Billman Current Opinion in Investigational Drugs 2002, 3 :1483-1486 (11 [PDF ] [PubMed ] [Related articles ]
Overview - Female sexual dysfunction. M Wyllie Current Opinion in Investigational Drugs 2002, 3 :1487-1488 (11 [PDF ] [PubMed ] [Related articles ]
Phosphodiesterase inhibitors for the treatment of erectile dysfunction. A Kuthe, F Montorsi, K-E Andersson, CG Stief Current Opinion in Investigational Drugs 2002, 3 :1489-1495 (11 [PDF ] [PubMed ] [Related articles ]
Alvimopan (Adolor/GlaxoSmithKline). IA Azodo, ED Ehrenpreis Current Opinion in Investigational Drugs 2002, 3 :1496-1501 (11 [PDF ] [PubMed ] [Related articles ]
Palonosetron (Helsinn). G Stacher Current Opinion in Investigational Drugs 2002, 3 :1502-1507 (11 [PDF ] [PubMed ] [Related articles ]
(S)-oxybutynin (Sepracor) RR Dmochowski Current Opinion in Investigational Drugs 2002, 3 :1508-1511 (11 [PDF ] [PubMed ] [Related articles ]
DNA topoisomerases in cancer chemotherapy: Using enzymes to generate selective DNA damage JL Nitiss Current Opinion in Investigational Drugs 2002, 3 :1512-1516 (11 [PDF ] [PubMed ] [Related articles ]
Irofulven (MGI Pharma) M Baekelandt Current Opinion in Investigational Drugs 2002, 3 :1517-1526 (11 [PDF ] [PubMed ] [Related articles ]
Glufosfamide (Baxter Oncology) I Niculescu-Duvaz Current Opinion in Investigational Drugs 2002, 3 :1527-1532 (11 [PDF ] [PubMed ] [Related articles ]
Troxacitabine (Shire Pharmaceuticals) G Ecker Current Opinion in Investigational Drugs 2002, 3 :1533-1538 (11 [PDF ] [PubMed ] [Related articles ]
Paper alert E Boven, G Damia, S Doggrell, RE Hurst, M Williams Current Opinion in Investigational Drugs 2002, 3 :1539-1546 (14 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1547-1549 (14 [PDF ]
Patent alert HAM Mucke, P Norman, N Press Current Opinion in Investigational Drugs 2002, 3 :1550-1560 (14 [PDF ]
Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients R Snoeck, Clercq E De Current Opinion in Investigational Drugs 2002, 3 :1561-1566 (14 [PDF ] [PubMed ] [Related articles ]
Strategies for the identification of inhibitors of West Nile virus and other flaviviruses P Shi Current Opinion in Investigational Drugs 2002, 3 :1567-1573 (14 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
The role of viruses in human cancer development and antiviral approaches for intervention JF Kadow, Ren A Regueiro, SP Weinheimer Current Opinion in Investigational Drugs 2002, 3 :1574-1579 (14 [PDF ] [PubMed ] [Related articles ]
ACH-126443 (Achillion/Yale University) J Patel, AK Mitra Current Opinion in Investigational Drugs 2002, 3 :1580-1584 (14 [PDF ] [PubMed ] [Related articles ]
Viramidine (Ribapharm) D Barnard Current Opinion in Investigational Drugs 2002, 3 :1585-1589 (14 [PDF ] [PubMed ] [Related articles ]
Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases G Girolomoni, S Pastore, C Albanesi, A Cavani Current Opinion in Investigational Drugs 2002, 3 :1590-1595 (14 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Novel therapies for atopic eczema M Worm Current Opinion in Investigational Drugs 2002, 3 :1596-1603 (14 [PDF ] [PubMed ] [Related articles ]
PVAC (Corixa/Genesis/Medicis) CS Leopold, HI Maibach Current Opinion in Investigational Drugs 2002, 3 :1604-1607 (14 [PDF ] [PubMed ] [Related articles ]
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and Type II diabetes G Liu, JM Trevillyan Current Opinion in Investigational Drugs 2002, 3 :1608-1616 (14 [PDF ] [PubMed ] [Related articles ]
Glucagon receptor antagonists for the treatment of Type II diabetes: Current prospects SW Djuric, N Girhalde, CW Lin Current Opinion in Investigational Drugs 2002, 3 :1617-1623 (14 [PDF ] [PubMed ] [Related articles ]
TAK-677 (Dainippon/Takeda) S Francke Current Opinion in Investigational Drugs 2002, 3 :1624-1628 (14 [PDF ] [PubMed ] [Related articles ]
Transdermal testosterone gel (Cellegy) Lee NJ McGriff Current Opinion in Investigational Drugs 2002, 3 :1629-1632 (14 [PDF ] [PubMed ] [Related articles ]
Muscarinic agonists as preventative therapy for Alzheimer's disease TG Beach Current Opinion in Investigational Drugs 2002, 3 :1633-1636 (15 [PDF ] [PubMed ] [Related articles ]
Role of CRH in the pathogenesis of dementia of Alzheimer's type and other dementias HU Rehman Current Opinion in Investigational Drugs 2002, 3 :1637-1642 (15 [PDF ] [PubMed ] [Related articles ]
Drug treatment for HIV-1-associated dementia Giesen HJ von, G Arendt Current Opinion in Investigational Drugs 2002, 3 :1643-1646 (15 [PDF ] [PubMed ] [Related articles ]
Altropane (Boston Life Science) F Cattabeni Current Opinion in Investigational Drugs 2002, 3 :1647-1651 (15 [PDF ] [PubMed ] [Related articles ]
ABC transporters and inhibitors: New targets, new agents GD Leonard, O Polgar, SE Bates Current Opinion in Investigational Drugs 2002, 3 :1652-1651 (15 [PDF ] [PubMed ] [Related articles ]
Enhancement of radiation therapy by vascular targeting agents DW Siemann, MR Horsman Current Opinion in Investigational Drugs 2002, 3 :1660-1665 (15 [PDF ] [PubMed ] [Related articles ]
ONT-093 (Ontogen) P Mistry, A Folkes Current Opinion in Investigational Drugs 2002, 3 :1666-1671 (15 [PDF ] [PubMed ] [Related articles ]
Metvix (PhotoCure) K Gardlo, T Ruzicka Current Opinion in Investigational Drugs 2002, 3 :1672-1678 (15 [PDF ] [PubMed ] [Related articles ]
Paper alert E Boven, S Doggrell, RE Hurst, M Williams Current Opinion in Investigational Drugs 2002, 3 :1679-1686 (16 [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2002, 3 :1687-1688 (16 [PDF ]
Patent alert I Duncan, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2002, 3 :1689-1700 (16 [PDF ]
Antibacterial agents: Patent highlights January to June 2002 OA Phillips, WC Matowe Current Opinion in Investigational Drugs 2002, 3 :1701-1711 (16 [PDF ] [PubMed ] [Related articles ]
Novel targets for antibiotic drug design ST Ali, AE Gill, A Lewendon Current Opinion in Investigational Drugs 2002, 3 :1712-1717 (16 [PDF ] [PubMed ] [Related articles ]
Overview - Heat shock proteins in stroke and neurodegenerative diseases R Urbanics Current Opinion in Investigational Drugs 2002, 3 :1718-1719 (16 [PDF ] [PubMed ] [Related articles ]
Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis P Weydt, MD Weiss, T Moller, GT Carter Current Opinion in Investigational Drugs 2002, 3 :1720-1724 (16 [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Anti-inflammatory strategies in coronary atherosclerosis PBJ Burton, TO Daniel Current Opinion in Investigational Drugs 2002, 3 :1725-1728 (16 [PDF ] [PubMed ] [Related articles ]
Third generation thrombolytics for the treatment of ischemic stroke AI Qureshi, RU PAnde, SH Kim, RA Hanel, JF Kirmani, AM Yahia Current Opinion in Investigational Drugs 2002, 3 :1729-1732 (16 [PDF ] [PubMed ] [Related articles ]
BIII-890-CL (Boehringer Ingelheim) J Meythaler Current Opinion in Investigational Drugs 2002, 3 :1733-1735 (16 [PDF ] [PubMed ] [Related articles ]
ZK-807834 (Berlex) U Sinha Current Opinion in Investigational Drugs 2002, 3 :1736-1741 (16 [PDF ] [PubMed ] [Related articles ]
Overview - Translation of developmental biology into therapeutics: The hedgehog signaling pathway and neurodegenerative diseases KL Allendoerfer, H Dudek Current Opinion in Investigational Drugs 2002, 3 :1742-1744 (16 [PDF ] [PubMed ] [Related articles ]
Caspases and neuroprotection J Bilsland, S Harper Current Opinion in Investigational Drugs 2002, 3 :1745-1752 (16 [PDF ] [PubMed ] [Related articles ]
Neurotrophins, neuroprotection and the blood-brain barrier WM Pardridge Current Opinion in Investigational Drugs 2002, 3 :1753-1757 (16 [PDF ] [PubMed ] [Related articles ]
NXY-059 (Centaur) PA Lapchak Current Opinion in Investigational Drugs 2002, 3 :1758-1762 (16 [PDF ] [PubMed ] [Related articles ]
CPI-1189 (Centaur) T Muller Current Opinion in Investigational Drugs 2002, 3 :1763-1767 (16 [PDF ] [PubMed ] [Related articles ]
Selectively replicating adenoviruses for cancer therapy: An update on clinical development LE Post Current Opinion in Investigational Drugs 2002, 3 :1768-1772 (16 [PDF ] [PubMed ] [Related articles ]
INGN-241 (Introgen) R Gopalkrishnan Current Opinion in Investigational Drugs 2002, 3 :1773-1777 (16 [PDF ] [PubMed ] [Related articles ]
Erratum Current Opinion in Investigational Drugs 2002, 3 :1778 (16 [PDF ]
Current Opinion in Investigational Drugs Volumes
previous issue
January